Canada's "high-cost" generic medicines require action, Competition Bureau states

The issue of generic drug costs has been a major topic in Canada in recent days, although the coalition government's crisis has, to some extent, overshadowed this. A report from the Competition Bureau has confirmed that domestic drug prices for non-branded products are higher than in the neighboring USA, at a time when patented agents are significantly cheaper. The Bureau makes a number of proposals to remedy the situation. Meanwhile, the Supreme Court of Canada has rejected an appeal which would have allowed a C$3.9 billion ($3.10 billion) class action against nine generic drugmakers for what were ruled unfounded claims of illegal rebates to pharmacists.